Comparison · NCT04893018-sae
NT-I7 (Efineptakin Alfa) Dose Level 1 vs NT-I7 (Efineptakin Alfa) Dose Level 2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NT-I7 (Efineptakin Alfa) Dose Level 1 vs NT-I7 (Efineptakin Alfa) Dose Level 2: serious adverse events. Trial comparisons, record NCT04893018-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04893018-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk in group 2 | 0.5 | 0.0945 | 0.905 | wilson | |
| Risk difference, group 1 minus group 2 | -0.333 | -0.761 | 0.234 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.333 | 0.0347 | 3.2 | log | |
| Odds ratio, group 1 over group 2 | 0.2 | 0.006 | 6.66 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on NT-I7 (Efineptakin Alfa) Dose Level 1 than on NT-I7 (Efineptakin Alfa) Dose Level 2 | 3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NT-I7 (Efineptakin Alfa) Dose Level 1 | Participants receive 480 µg/kg NT-I7 (Efineptakin alfa) IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~NT-I7 (Efineptakin alfa): Given IM | 1 | 6 | EG000 |
| Group 2 | NT-I7 (Efineptakin Alfa) Dose Level 2 | Participants receive 960 µg/kg NT-I7 (Efineptakin alfa) IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~NT-I7 (Efineptakin alfa): Given IM | 1 | 2 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-Cause Mortality was assessed through study completion, up to 12 months; serious adverse events and other (not including serious) adverse events were assessed from the time of the first dose until 30 days after the last dose of NT-I7, approximately 31 weeks total.
Source ClinicalTrials.gov
Trial
- Title
- NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
- NCT number
- NCT04893018
- Phases
- PHASE1
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
- Interventions
- Efineptakin alfa
- Lead sponsor
- Fred Hutchinson Cancer Center
- Results first posted
- 2024-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04893018?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04893018-sae